Preclinical results encouraged the enrollment of STS patients in early-phase clinical trials of IGF1-R inhibitors, one of which is figitumumab, whose clinical efficacy against STSs including Ewing sarcoma was evaluated [58,59]. This evidence concerns the gene IGF1R and Ewing sarcoma.